These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 26073829)

  • 1. Fibrinogen and catheter-directed thrombolysis.
    Ross RL; Beck AW
    Semin Vasc Surg; 2014 Dec; 27(3-4):182-95. PubMed ID: 26073829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fibrinogen Level and Bleeding Risk During Catheter-Directed Thrombolysis Using Tissue Plasminogen Activator.
    Lee K; Istl A; Dubois L; DeRose G; Forbes TL; Wiseman D; Mujoomdar A; Kribs S; Power AH
    Vasc Endovascular Surg; 2015 Oct; 49(7):175-9. PubMed ID: 26462979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibrinogen level as a surrogate for the outcome of thrombolytic therapy using tissue plasminogen activator for acute lower extremity intravascular thrombosis.
    Skeik N; Gits CC; Ehrenwald E; Cragg AH
    Vasc Endovascular Surg; 2013 Oct; 47(7):519-23. PubMed ID: 23899656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma fibrinogen level as a potential predictor of hemorrhagic complications after catheter-directed thrombolysis for peripheral arterial occlusions.
    Poorthuis MHF; Brand EC; Hazenberg CEVB; Schutgens REG; Westerink J; Moll FL; de Borst GJ
    J Vasc Surg; 2017 May; 65(5):1519-1527.e26. PubMed ID: 28274749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of catheter-delivered plasmin in patients with acute lower extremity arterial or bypass graft occlusion: phase I results.
    Marder VJ; Comerota AJ; Shlansky-Goldberg RD; Davis JP; Deng C; Hanna K; Fineberg D
    J Thromb Haemost; 2012 Jun; 10(6):985-91. PubMed ID: 22487025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibrinogen Degradation Speed as a Predictor of Major Bleeding Complications During Catheter Directed Thrombolysis in Patients with Acute Lower Limb Ischaemia.
    Leenstra B; van Ginkel DJ; Huitema ADR; Verhoeven BAN; Vonken EJ; de Borst GJ
    Eur J Vasc Endovasc Surg; 2021 May; 61(5):861-862. PubMed ID: 33583709
    [No Abstract]   [Full Text] [Related]  

  • 7. The association of periprocedural hypertension and adverse outcomes in patients undergoing catheter-directed thrombolysis.
    Agle SC; McNally MM; Powell CS; Bogey WM; Parker FM; Stoner MC
    Ann Vasc Surg; 2010 Jul; 24(5):609-14. PubMed ID: 20413257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute phase treatment of venous thromboembolism: advanced therapy. Systemic fibrinolysis and pharmacomechanical therapy.
    Konstantinides SV; Wärntges S
    Thromb Haemost; 2015 Jun; 113(6):1202-9. PubMed ID: 25789580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Acute iliofemoral deep venous thrombosis should be treated with catheter-directed thrombolysis].
    Broholm R; Just S; Jørgensen M; Bækgaard N
    Ugeskr Laeger; 2012 Apr; 174(14):930-3. PubMed ID: 22469160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Should Age Limit the Use of Catheter-Directed Thrombolysis: Results of National Survey.
    Al-Nouri O; Sinacore J; Halandras P; Hershberger R
    Vasc Endovascular Surg; 2015; 49(1-2):4-7. PubMed ID: 25835023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of catheter-directed thrombolysis for iliofemoral venous thrombosis.
    Grossman C; McPherson S
    AJR Am J Roentgenol; 1999 Mar; 172(3):667-72. PubMed ID: 10063857
    [No Abstract]   [Full Text] [Related]  

  • 12. Safety of catheter-directed thrombolysis for deep venous thrombosis in cancer patients.
    Kim HS; Preece SR; Black JH; Pham LD; Streiff MB
    J Vasc Surg; 2008 Feb; 47(2):388-94. PubMed ID: 18241762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The value of laboratory diagnosis in thrombolytic therapy].
    Ostermann H; Kienast J
    Internist (Berl); 1992 Apr; 33(4):252-7. PubMed ID: 1612849
    [No Abstract]   [Full Text] [Related]  

  • 14. Comparative outcomes of catheter-directed thrombolysis plus anticoagulation versus anticoagulation alone in the treatment of inferior vena caval thrombosis.
    Alkhouli M; Zack CJ; Zhao H; Shafi I; Bashir R
    Circ Cardiovasc Interv; 2015 Feb; 8(2):e001882. PubMed ID: 25663321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Local thrombolysis: a newer approach to treating inflammatory bowel disease-related thromboembolism.
    Tabibian JH; Roth BE
    J Clin Gastroenterol; 2009; 43(5):391-8. PubMed ID: 19247203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thrombolytic therapy: clinical applications.
    Baker WF
    Hematol Oncol Clin North Am; 2003 Feb; 17(1):283-311. PubMed ID: 12627672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term outcomes of low-dose catheter-directed thrombolytic therapy: a 5-year single-center experience.
    Sebastian AJ; Robinson GJ; Dyet JF; Ettles DF
    J Vasc Interv Radiol; 2010 Jul; 21(7):1004-10. PubMed ID: 20570176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantity of clot lysed after catheter-directed thrombolysis for iliofemoral deep venous thrombosis correlates with postthrombotic morbidity.
    Grewal NK; Martinez JT; Andrews L; Comerota AJ
    J Vasc Surg; 2010 May; 51(5):1209-14. PubMed ID: 20347543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and feasibility of ultrasound-accelerated catheter-directed thrombolysis in deep vein thrombosis.
    Grommes J; Strijkers R; Greiner A; Mahnken AH; Wittens CH
    Eur J Vasc Endovasc Surg; 2011 Apr; 41(4):526-32. PubMed ID: 21256773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Streptodecase-2 in the treatment of acute myocardial infarct, unstable stenocardia, thromboembolism and thrombosis].
    Butorov VN; Repinskaia NP; Demidova AV; Sysoeva NA; Kirichenko AA
    Ter Arkh; 1990; 62(8):21-6. PubMed ID: 2274864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.